Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials
Rattachement africain : ar. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Shortages of component two of Sputnik V vaccine (rAd5) are delaying the possibility of achieving full immunisation. The immunogenic response associated with the use of alternative schemes to complete the scheme was not explored. METHODS: We did two non-inferiority randomized clinical trials with outcomes measures blinded to investigators on adults aged 21-65 years, vaccinated with a single dose of rAd26 ≥ 30 days before screening and no history of SARS-CoV-2. Participants were assigned (1:1:1:1:1) to receive either rAd5; ChAdOx1; rAd26; mRNA-1273 or BBIBP-CorV. The primary endpoint was the geometric mean ratio (GMR) of SARS-CoV-2 anti-spike IgG concentration at 28 days after the second dose, when comparing rAd26/rAd5 with rAd26/ChAdOx1, rAd26/rAd26, rAd26/mRNAmRNA-1273 and rAd26/BBIBP-CorV. Serum neutralizing capacity was evaluated using wild type SARS-CoV-2 reference strain 2019 B.1. The safety outcome was 28-day rate of serious adverse. The primary analysis included all participants who received ≥ 1 dose. The studies were registered with NCT04962906 and NCT05027672. Both trials were conducted in Buenos Aires, Argentina. FINDINGS: =65). 524 participants completed the study. As compared with rAd26/rAd5 (1·00), the GMR (95%CI) at day 28 was 0·65 (0·51-0·84) among those who received ChAdOx1; 0·47 (0·34-0·66) in rAd5; 3·53 (2·68-4·65) in mRNA-1273 and 0·23 (0·16-0·33) in BBIBP-CorV. The geometric mean (IU/ml) from baseline to day 28 within each group increased significantly with ChAdOx1 (4·08 (3·07-5·43)); rAd26 (2·69 (1·76-4·11)); mRNA-1273 (21·98 (15·45-31·08)) but not in BBIBP-CorV (1·22 (0·80-1·87)). INTERPRETATION: Except for mRNA-1273 which proved superior, in all other alternatives non-inferiority was rejected. Antibody concentration increased in all non-replicating viral vector and RNA platforms. FUNDING: The trials were supported (including funding, material support in the form of vaccines and testing supplies) by the Buenos Aires City Government.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials
- Date Crossref
- 01/05/2022
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Ministerio de Salud pays non établi dans la noticeOrganisme public
-
Hospital Muñiz pays non établi dans la noticeÉtablissement de santé
-
Consejo Nacional de Investigaciones Científicas y Técnicas pays non établi dans la noticeOrganisme public
-
Universidad de Buenos Aires pays non établi dans la noticeUniversité ou école supérieure
-
Instituto de Investigaciones Biomédicas en Retrovirus y Sida Consejo Nacional de Investigaciones Científicas y Técnicas pays non établi dans la noticeStructure de recherche
-
Hospital General de Niños Ricardo Gutierrez pays non établi dans la noticeÉtablissement de santé
-
Subsecretaría de Planificación Sanitaria pays non établi dans la noticeInstitution
-
División Análisis Clínicos pays non établi dans la noticeÉtablissement de santé
-
Hospital "Francisco J. Muñiz" Unidad de Virología pays non établi dans la noticeÉtablissement de santé
-
Hospital de Niños Dr. Ricardo Gutiérrez pays non établi dans la noticeÉtablissement de santé
Ministerio de Salud, Hospital Muñiz et Consejo Nacional de Investigaciones Científicas y Técnicas, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.